CEO received an award of 38K BIIB derivative securities | OQRO Insider tradesWhy it stands out
Compensation award — excluded from discretionary-purchase analysis.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
All the details
Dates, kept separate
- Transaction date
- Feb 13, 2026
- Reporting period
- Not applicable
- Filed with the SEC
- Feb 18, 2026
CEOGrant / award
Context
- Classification
grant award
Code A — grant or award
- Planned / mechanical clue
Footnote references vesting of compensation awards
Only flagged when a footnote says so; never inferred
Source receipt
- Record ID
- 0000875045-26-000035
- Filed / recorded
Added to OQROOct 2, 2026, 12:27 PM UTC Data qualityVerified: identifiers matched exactly Reporting personChristopher Viehbacher RelationshipDirector, Officer Officer titlePresident and CEO SecurityRestricted Stock Unit TableDerivative (Table II) Transaction dateFeb 13, 2026 Acquired / disposedAcquired (A) Footnotes from the filing
- The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the grant date of February 13, 2026.
Around the same time
Compensation award — excluded from discretionary-purchase analysis.
Biogen's Head of Pharm Ops and Tech spent $585 of their very own money to buy Biogen shares.
Compensation award — excluded from discretionary-purchase analysis.
